{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:19:14Z","timestamp":1772194754154,"version":"3.50.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T00:00:00Z","timestamp":1430265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0125080","type":"journal-article","created":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T13:54:24Z","timestamp":1430315664000},"page":"e0125080","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy"],"prefix":"10.1371","volume":"10","author":[{"given":"Karin","family":"Neukam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela I.","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattias","family":"Mandorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Bhagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Haberl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Stoeckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Scholten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"de los Santos-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Mauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcial","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juergen K.","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,4,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/cit103","article-title":"Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV\/hepatitis C virus-coinfected patients with compensated cirrhosis","volume":"56","author":"JA Mira","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.2012.7844","article-title":"Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV\/HCV","volume":"308","author":"BN Limketkai","year":"2012","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1097\/QAD.0b013e3283568884","article-title":"Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients","volume":"26","author":"JA Mira","year":"2012","journal-title":"AIDS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"F Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"BR Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"IM Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"S Zeuzem","year":"2011","journal-title":"New Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","article-title":"Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial","volume":"13","author":"M Sulkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","article-title":"Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial","volume":"159","author":"MS Sulkowski","year":"2013","journal-title":"Ann Intern Med"},{"issue":"Suppl. 2","key":"ref10","article-title":"Global Antiviral Journal","volume":"9","author":"CB Hare","year":"2013"},{"key":"ref11","unstructured":"Montes M, Nelson M, Girard M, Sasadeusz J, Horban A, Grinsztejn B, al. (2013) Telaprevir combination therapy in treatment-naive and-experienced patients co-infected with hepatitis C virus and HIV: Week 12 analysis of INSIGHT [abstract 38]. In: Program and Abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (Washington DC). Alexandria, VA: American Association for the Study of Liver Disease."},{"key":"ref12","unstructured":"European AIDS Clinical Society (EACS). Clinical Management and Treatment of Chronic HBV and HCV Co-infection in HIV-positive Persons. Available: http:\/\/www.eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf<\/ext-link>. Accessed 30 2014."},{"key":"ref13","unstructured":"European Association for the Study of the Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2014. Available: http:\/\/files.easl.eu\/easl-recommendations-on-treatment-of-hepatitis-C.pdf<\/ext-link>. Accessed 27 August 2014."},{"key":"ref14","unstructured":"Poizot-Martin I, Bellissant E, Colson P, Renault A, Piroth L, Solas C, et al. (2014) Boceprevir for previously treated HCV-HIV coinfected patients: the ARNS-HC27 BocepreVIH Trial [abstract 659LB]. In: Program and Abstracts of the 21st Conference on Retroviruses and Opportunistic Infections (Boston). Boston, MA: Infectious Diseases Society of America."},{"issue":"15","key":"ref15","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/cid\/ciu659","article-title":"Telaprevir for HIV-HCV coinfected patients failing peginterferon-ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial","volume":"59","author":"L Cotte","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of Telaprevir or Boceprevir in Treatment-experienced Patients with HCV Genotype 1 Infection and Cirrhosis","volume":"147","author":"C Hezode","year":"2014","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/gutjnl-2013-305667","article-title":"Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C","volume":"63","author":"M Colombo","year":"2013","journal-title":"Gut"},{"issue":"Suppl 4","key":"ref18","first-page":"6","article-title":"New triple therapy for chronic hepatitis C: real life clinical experience in a community setting","volume":"72","author":"MJ Akiyama","year":"2013","journal-title":"Hawaii J Med Public Health"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cgh.2013.12.011","article-title":"Similar Effectiveness of Boceprevir and Telaprevir Treatment Regimens for Hepatitis C Virus Infection on the Basis of a Nationwide Study of Veterans","volume":"12","author":"GN Ioannou","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref20","unstructured":"Di Bisceglie A, Kuo A, Rustgi V, Sulkowski MS, Sterling RK, Stewart T, et al. (2013)Virologic Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR) in the United States (HCV-TARGET) [abstract 41]. In: Program and Abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (Washington DC). Alexandria, VA: American Association for the Study of Liver Disease."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jvh.12145","article-title":"Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment","volume":"21","author":"CR Werner","year":"2014","journal-title":"J Viral Hepat"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.15403\/jgld-1278","article-title":"A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis","volume":"23","author":"L Gheorghe","year":"2014","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref23","unstructured":"European AIDS Clinical Society. Clinical Management and Treatment of Chronic HBV and HCV Co-infection in HIV-positive Persons. Available: http:\/\/eacsociety.org\/Portals\/0\/Guidelines_Online_131014.pdf<\/ext-link>. Accessed 30 November 2014."},{"key":"ref24","unstructured":"INCIVEK (telaprevir) full prescribing description. Available: http:\/\/pi.vrtx.com\/files\/uspi_telaprevir.pdf<\/ext-link>. Accessed 30 August 2014."},{"key":"ref25","unstructured":"VICTRELIS (boceprevir) full prescribing description. Available: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf<\/ext-link>. Accessed 3 October 2014."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment","volume":"13","author":"PJ Scheuer","year":"1991","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/521857","article-title":"The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection","volume":"45","author":"S Vergara","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jac\/dkm373","article-title":"Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus\/HIV-coinfected patients","volume":"60","author":"JA Pineda","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/135965350601100207","article-title":"Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study","volume":"11","author":"AS Zinkernagel","year":"2006","journal-title":"Antivir Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/QAD.0b013e32836138d0","article-title":"Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous anti hepatitis C virus therapy: 24-week results","volume":"27","author":"K Lacombe","year":"2013","journal-title":"AIDS"},{"key":"ref31","unstructured":"Martel-Laferriere V, Brinkley V, Bichoupan K, Posner S, Stivala A, Perumalswami P, et al. (2013) On-treatment responses to telaprevir-based hepatitis C treatment are similar in HIV\/Hepatitis C Virus co-infected and Hepatitis C Virus mono-infected patients [abstract 679]. In: Program and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections (Atlanta). Boston, MA: Infectious Diseases Society of America."},{"key":"ref32","unstructured":"von Wichmann MA, Moreno A, Ortega E, Mira JA, Montes M, Tellez MJ, et al. (2013) Efficacy and safety of therapy with Telaprevir (DAA) in genotype 1 coinfected patients with advanced fibrosis. Six month follow-up data. [abstract 1874]. In: Program and Abstracts of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (Washington DC). Alexandria, VA: American Association for the Study of Liver Disease."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jhep.2014.03.022","article-title":"Safety & Efficacy of Boceprevir\/Peginterferon\/Ribavirin for HCV G1 Compensated Cirrhotics: Meta-Analysis of 5 Trials","volume":"61","author":"JM Vierling","year":"2014","journal-title":"J Hepatol"},{"key":"ref34","unstructured":"A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon \/Ribavirin. Available: http:\/\/clinicaltrials.gov\/show\/NCT01718301<\/ext-link>. Accessed 3 October 2014."},{"key":"ref35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/infdis\/jiu516","article-title":"Response-guided Boceprevir-based Triple-Therapy in HIV\/HCV-coinfected Patients: The HIVCOBOC-RGT Study","volume":"211","author":"M Mandorfer","year":"2014","journal-title":"J Infect Dis"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1086\/605676","article-title":"Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients","volume":"49","author":"JA Pineda","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref37","unstructured":"U.S. Food and Drug Administration. Olysio (simeprevir) for the treatment of chronic hepatitis C in combination antiviral treatment. Available: http:\/\/www.fda.gov\/forconsumers\/byaudience\/forpatientadvocates\/ucm377234.htm<\/ext-link>. Accessed 3 December 2014."},{"key":"ref38","unstructured":"U.S. Food and Drug Administration. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. Available: http:\/\/www.fda.gov\/forconsumers\/byaudience\/forpatientadvocates\/ucm377920.htm<\/ext-link> Accessed 3 December 2014."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0125080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:50:35Z","timestamp":1748353835000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0125080"}},"subtitle":[],"editor":[{"given":"Wenyu","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,29]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0125080","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725453625.793506497","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,29]]}}}